Skip to main content
Premium Trial:

Request an Annual Quote

EnviroLogix Teams with Ionian Technologies on Ag-Bio Genetic Tests

NEW YORK (GenomeWeb News) – EnviroLogix and Ionian Technologies will partner to develop, make, and sell rapid tests that could detect genes or gene sequences for use by agricultural biotech customers, EnviroLogix said today. 
Under the collaborative development agreement, EnviroLogix will identify gene targets and seed biotechnology companies, and then sell Ionian’s rapid nucleic acid-based tests that these companies could use either in the lab or out in the fields.
Ionian's test methods are sensitive enough to detect single base changes between two otherwise similar sequences, EnviroLogix said. In addition, it noted that the technology can perform isothermal amplification of either DNA or RNA in around 5 minutes, offering a significant speed advantage over other thermal cycling technologies.
Portland, Me.-based EnviroLogix develops, manufactures, and sells immunoassays for detection of molds, mycotoxins, algal toxins, pesticides, and plant pathogens.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.